Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00495716 · ClinicalTrials.gov registry record · Phase 4

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

A Phase 4 study, sponsored by University of Washington.

Terminated
Registry status
Phase 4
Development phase
72
Enrollment target

NCT00495716: Clinical Trial Phase 4 study, sponsored by University of Washington.

NCT00495716 is a Phase 4 study that was terminated before completion, run by University of Washington. The registered enrollment target is 72 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00495716, a Phase 4 study, was terminated before completion, sponsored by University of Washington.

TERMINATED
Registry status
Phase 4
Development phase
72 participants
Enrollment target

Study Summary

The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners. Study terminated; investigator relocated and study funding ended. Results were never analyzed because data were not collected.

Interventions

  • DRUG acyclovir

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2008-01
Est. Completion 2010-06
Phase Phase 4
University of Washington

1,048 total trials

Why NCT00495716 stopped before completion

NCT00495716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 1 intervention - of which acyclovir is the first listed.

NCT00495716 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00495716 about?

NCT00495716 is a clinical study titled "Effect of HSV-2 Suppressive Therapy on Sexual Behavior". The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners. Study terminated; investigator relocated and study funding ended. Results were never analyzed because data wer...

What is the current status of trial NCT00495716?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2008-01. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00495716?

The interventions under investigation include: acyclovir (DRUG).

Who is sponsoring clinical trial NCT00495716?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00495716's enrollment target sits among peer trials

72 1035th of 2000 higher than 961 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00495716, the US trial registry maintained by the National Library of Medicine. NCT00495716 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.